Applied Immune Sciences Inc. has signed a licensing anddistribution agreement with Asahi Medical Co. Ltd. of Japan forthe Menlo Park, Calif., company's cell separator devices.
Asahi will conduct clinical trials, pursue regulatory approvalsand market three CELLector applications in the Pacific Rim,except for Australia and New Zealand, where AIS retains rights.
The agreement was completed for a seven-figure payment, thecompanies announced Thursday.
Asahi will pay royalties on sales, and after meeting certainsales milestones could be given manufacturing rights on theseparators, said AIS spokesman Jack Martin.
The separators covered by the agreement are one that sifts outstem cells and two that remove cells believed to cause graft-vs.-host disease, both from bone marrow. The companies lastyear completed an agreement covering a separator used inlaboratory research.
AIS shares (NASDAQ:AISX) closed at $18.75, down $1.25. -- RF
(c) 1997 American Health Consultants. All rights reserved.